Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2022

View Archived Issues

SIGLEC15 promotes immune system evasion in lymphoma

TL-532 induces life-long antitumor autovaccination and cross-immunity against unrelated cancers

Rheinische Friederich-Wilhelms-Universitaet Bonn discloses MRGPRX4 agonists

Chinese researchers describe new ADCs for cancer

Proxygen and collaborators present new compounds for cancer

AC Immune synthesizes MAPT aggregation inhibitors

Accent Therapeutics discloses METTL3 inhibitors

Targeting BCL10-MALT1 interaction blocks ABC-DLBCL xenograft tumor growth

Type 2 diabetes getting precision medicine makeover

MALT1 promotes glioblastoma pathogenesis and emerges as a potential therapeutic target

Celsion advances PLACCINE DNA-based vaccine platform to proof-of-concept NHP studies

NexImmune, Yale and JDRF partner to explore AIM nanoparticles with teplizumab for type 1 diabetes

NodThera announces addition of third NLRP3 inflammasome inhibitor to pipeline

Incannex's IHL-216A shows neuroprotective effect in rodent model of sports concussion

Galectin-8 as a novel target for the treatment of bacterial keratitis

Investigators present new murine model of Kcnv2-mutated CDSRR

Long noncoding RNA LOC100506453 found as useful for treatment monitoring in APL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...